

PALLADINI Arianna

Researcher unique identifier (ORCID): 0000-0001-6105-4895

EDUCATION

2021-PhD in Oncology, Haematology and Pathology, University of Bologna, Italy. Supervisor: Prof. P-L Lollini. Thesis: "Therapeutic strategies to overcome tumor heterogeneity in HER2 positive mammary carcinoma".

2020-Italian National Scientific Qualification for Associate Professor of General Pathology

2009-PhD in Cellular and Molecular Biotechnology, University of Bologna, Italy. Supervisor: Prof. SM Spampinato. Thesis: "Preclinical development of cancer vaccines".

2002-Master degree in Biotechnology, University of Bologna, Italy. Supervisor: Prof. R Cevenini. Co-Supervisor: Prof. V Sambri. Thesis: "Cloning and expression of CagA gene of Helicobacter Pylori: diagnostic relevance". Mark: 110/110 cum laude.

CURRENT POSITION

2025-now Associate Professor, Department of Molecular Medicine, University of Pavia, Italy. PI of the Tumor Immunology and Cancer Vaccines Laboratory.

(<https://medicinamolecolare.dip.unipv.it/en/research/research-teams-and-topics/immunology-and-general-pathology/tumor-immunology-and-cancer>)

2024-now, Researcher of the Oncology Platform of Fondazione IRCCS Policlinico San Matteo of Pavia

PREVIOUS POSITIONS

2022-2025 Senior Assistant Professor, University of Pavia, Italy.

2021-2022 Junior Assistant Professor, University of Bologna, Italy.

2009-2021 Post-Doc researcher, University of Bologna, Italy.

2006-2008 PhD student, University of Bologna, Italy.

2003-2006 Research fellow, University of Bologna, Italy.

SUPERVISION AND CO-SUPERVISION OF GRADUATE STUDENTS AND POSTDOCTORAL FELLOWS

2022-now supervisor 7 Bachelor's degree students in Biotechnology/Biology, 11 Master's degree students in Biology/Medical and Pharmaceutical Biotechnology and 4 PhD student in Translational Medicine at the University of Pavia (Italy).

2011-now co-supervisor 7 Master's degree students in Biology/Molecular and Industrial Biotechnology/ Medicine and Surgery and 4 PhD students in Oncology at the University of Bologna (Italy).

EDITORING AND REVIEWING

2021-2023 Co-Editor: Frontiers in Oncology, Research Topic "Inhibitors of CDK family: New Perspective and Rationale for Drug Combination in Preclinical Model of Solid Tumors".

2020-2024 Member of the Reviewer Board of Cancers journal and Biomedicines

2016-now Reviewer for BMC Immunology, Immunopharmacology and Immunotoxicology, Cells, PlosOne, Theranostics, Science Translational Medicine, Journal of cell communication and signaling, NPJ Breast Cancer.

2025 Reviewer for the Dutch Research Council (NWO), Netherlands

2019 Reviewer for the Piemonte Orientale University, Italy

2017 Reviewer for the Executive government agency of National Science Centre of Poland

PUBLICATIONS

Papers: 57

Book chapters: 4

h-index: 22

Citations: 1395

Congresses: 60 poster/oral presentation including AACR annual meeting, ESMO annual meeting, WCLC, Senescl 2025

FUNDING

2026-now Project MSCA Doctoral Network "InnovaRTBRAIN" founded by Horizon Europe. Coordinator: Prof. Yolanda Prezado. Role: PI University of Pavia.

2026-now Project "Identification and targeting of N-Myc downstream-regulated gene (NDRG1) as a new biomarker for immunotherapy-resistant lung tumors: the ITAN Project" (Ricerca Corrente 2026 Call) founded by Mistry of Health-Fondazione IRCCS Policlinico San Matteo di Pavia. PI: Dott. Francesco Agustoni. Duration: 2 years. Role: Co-PI

2026-now Project "Next-Generation Immunotherapy: T Cell Function as a Predictive and Tuning Tool" founded by The Global Lung Cancer Impact Challenge. Duration: 4 years. Role: PI.

2026-now Project BIOMBRT "Unravelling the biological mechanisms of normal tissue preservation in spatially fractionated minibeam radiation therapy" founded by European Union's "EURATOM" research and innovation program (Pianoforte Call). PI: Prof. Yolanda Prezado, University of Santiago de Compostela (USC). Duration: 4 years. Role: Responsible of the University of Pavia Project Partner.

2024-now Project "Identification of a multiplex Signature to Predict and Prevent Resistance to Immunotherapy in PD-L1 overexpressed Non-small cell lung Tumors: the SPRINT Project" (Ricerca Corrente 2024 Call) founded by Mistry of Health-Fondazione IRCCS Policlinico San Matteo di Pavia. PI:Dott. Francesco Agustoni. Duration: 2 years. Role: Co-PI

2020-2025 Project GR-2018-12368031 "Understanding molecular mechanisms of resistance to immune check-point inhibitors in advanced non-small cell lung cancer (NSCLC)" founded by Italian ministry of Health. PI: Dr. Francesco Gelsomino. Role: PI unit 2.

2019 Grant "Alte competenze per nuove imprese: laboratorio regionale per l'imprenditorialità POR FSE 2014/2020, competition "Call for Business Plan" of the University of Bologna.

2019 Think4Food award, Call4Ideas, research category

PROJECT PARTICIPATION AS CO-INVESTIGATOR

Fondazione Carisbo 2021, Bando di Ricerca Medica e Alte Tecnologie 2021. Principal Investigator: Prof. P-L Lollini. Topic: resistance to K-RAS TKI inhibitors in patients with advanced NSCLC. Role: Co-investigator.

Fondazione Carisbo 2019, Bando di ricerca medica II semestre 2019. Principal Investigator: Prof. Pier-Luigi Lollini. Topic: Rare mutations in lung cancer and mechanisms of resistance to targeted therapy. Role: Co-investigator.

ENTERPRISE ACTIVITIES

2021-2025: Co-founder of Lac2Lab Srls. Web-site: <https://www.lac2lab.com>.

PERIOD ABROAD

2015: Visiting fellow at VHIO, Barcelona, Spain. Growth Factors Laboratory. Supervisor: Dott. Joaquín Arribas. Research topic: study of HER2 isoforms and PHLDA1 gene.

PUBLICATIONS

1. Astolfi A, Landuzzi L, Nicoletti G, De Giovanni C, Croci S, Palladini A, Ferrini S, Iezzi M, Musiani P, Cavallo F, Forni G, Nanni P, Lollini P-L. (2005) Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. *American Journal of Pathology*; 166: 1205-1216.
2. Palladini A, Astolfi A, Croci S, De Giovanni C, Nicoletti G, Rosolen A, Sartori F, Lollini P-L, Landuzzi L, Nanni P. (2006) Endothelin-3 production by human rhabdomyosarcoma: a possible new marker with a paracrine role. *European Journal of Cancer*; 42: 680-687.
3. Croci S, Nicoletti G, Landuzzi L, Palladini A, Chiarini F, Nanni P, Lollini P-L, De Giovanni C. (2007) Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells. *Oncology Reports*; 18: 451- 456.
4. De Giovanni C, Croci S, Nicoletti G, Landuzzi L, Palladini A, Pannellini T, Borgia L, Iezzi M, Di Carlo E, Orengo AM, Kennedy RC, Lollini P-L, Nanni P, Musiani P. (2007) Inhibition of prostate carcinogenesis by combined active immunoprophylaxis. *International Journal of Cancer*; 121: 88-94.

5. Nanni P, Nicoletti G, Palladini A, Croci S, Murgo A, Antognoli A, Landuzzi L, Fabbi M, Ferrini S, Musiani P, Iezzi M, De Giovanni C, Lollini P-L. (2007) Antimetastatic activity of a preventive cancer vaccine. *Cancer Research*; 67: 11037-44. Erratum in: *Cancer Research*; 67, 12034.
6. Croci S, Landuzzi L, Nicoletti G, Palladini A, Antognoli A, De Giovanni C, Nanni P, Lollini P-L. (2007) Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis. *Pathology Oncology Research*; 13: 336-339.
7. Pappalardo F, Halling-Brown MD, Rapin N, Zhang P, Alemani D, Emerson A, Paci P, Duroux P, Pennisi M, Palladini A, Miotto O, Churchill D, Rossi E, Shepherd AJ, Moss DS, Castiglione F, Bernaschi M, Lefranc MP, Brunak S, Motta S, Lollini P-L, Basford KE, Brusica V. (2009) Immuno-Grid, an integrative environment for large-scale simulation of the immune system for vaccine discovery, design, and optimization. *Briefings in Bioinformatics*; 10: 330-340.
8. Nanni P, Nicoletti G, Palladini A, Astolfi A, Rinella P, Croci S, Landuzzi L, Antognoli A, Murgo A, Ianzano ML, De Giovanni C, Lollini P-L. (2009) Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4. *Molecular Cancer Therapeutics*; 8: 754-761.
9. De Giovanni C, Nicoletti G, Landuzzi L, Croci S, Palladini A, Antognoli A, Murgo A, Ianzano ML, Grosso V, Stivani V, Iezzi M, Musiani P, Nanni P, Lollini P-L. (2009) Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy. *Vaccine*; 27: 2065-2069.
10. De Giovanni C, Nicoletti G, Palladini A, Croci S, Landuzzi L, Antognoli A, Murgo A, Astolfi A, Ferrini S, Fabbi M, Amici A, Penichet ML, Aurisicchio L, Iezzi M, Musiani P, Nanni P, Lollini P-L. (2009) A multi-DNA preventive vaccine for p53/Neu driven cancer syndrome. *Human Gene Therapy*; 20:453-464.
11. Nanni P, Nicoletti G, Landuzzi L, Croci S, Murgo A, Palladini A, Antognoli A, Ianzano ML, Stivani V, Grosso V, Maira S-M, García-Echeverría C, Scotlandi K, De Giovanni C, Lollini P-L (2010). High metastatic efficiency of human sarcoma cells in Rag2/ γ c double knockout mice provides a powerful test system for antimetastatic targeted therapy. *European Journal of Cancer*; 46: 659-668.
12. Halling-Brown M, Pappalardo F, Rapin N, Zhang P, Alemani D, Emerson A, Castiglione F, Duroux P, Pennisi M, Miotto O, Churchill D, Rossi E, Moss DS, Sansom CE, Bernaschi M, Le Franc MP, Brunak S, Lund O, Motta S, Lollini P-L, Murgo A, Palladini A, Basford KE, Brusica V, Shepherd AJ. (2010) Immunogrid: towards agent-based simulations of the human immune system at a natural scale. *Philosophical Transactions. Series A, Mathematical, Physical, and Engineering Sciences*; 368: 2799-2815.
13. Palladini A, Nicoletti G, Pappalardo F, Murgo A, Grosso V, Stivani V, Ianzano ML, Antognoli A, Croci S, Landuzzi L, De Giovanni C, Nanni P, Motta S, Lollini P-L. (2010) In silico modeling and in vivo efficacy of cancer-preventive vaccinations. *Cancer Research*; 70: 7755- 7763.

14. Pennisi M, Pappalardo F, Palladini A, Nicoletti G, Nanni P, Lollini P-L, Motta S. (2010) Modeling the competition between lung metastases and the immune system using agents. *BMC Bioinformatics*; 11 (Suppl 7): S13.
15. Croci S, Recktenwald CV, Lichtenfels R, Nicoletti G, Dressler SP, De Giovanni C, Astolfi A, Palladini A, Shin-Ya K, Landuzzi L, Nanni P, Lollini P-L, Seliger B. (2010) Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system. *Proteomics*; 10: 3835-3853.
16. Landuzzi L, Antognoli A, Nicoletti G, Croci S, Palladini A, Ianzano ML, Murgo A, Stivani V, Grosso V, Nanni P, De Giovanni C, Lollini P-L. (2011) HER-2/neu tolerant and non-tolerant mice for fine assesment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines *Vaccine*; 29: 4690-4697.
17. Pappalardo F, Palladini A, Pennisi M, Castiglione F, Motta S. (2011) Mathematical and computational models in tumor immunology. *Mathematical Modelling of Natural Phenomena*; 7: 186-203.
18. Nanni P, Nicoletti G, Palladini A, Croci S, Murgo A, Ianzano ML, Grosso V, Stivani V, Antognoli A, Lamolinara A, Landuzzi L, di Tomaso E, Iezzi M, De Giovanni C, Lollini P-L. (2012) Multiorgan metastasis of human HER-2+ breast cancer in Rag2-/-;Il2rg-/- mice and treatment with PI3K inhibitor. *PLoS ONE*; 7: e39626-e39626.
19. De Giovanni C, Nicoletti G, Landuzzi L, Romani F, Croci S, Palladini A, Murgo A, Antognoli A, Ianzano ML, Stivani V, Grosso V, Iezzi M, Stramucci L, Barbieri E, Lemoli RM, Nanni P, Lollini P-L. (2012) Human responses against HER-2-positive cancer cells in human immune system-engrafted mice. *British Journal of Cancer*; 107: 1302 – 1309.
20. Nanni P, Gatta V, Menotti L, De Giovanni C, Ianzano M, Palladini A, Grosso V, Dall'Ora M, Croci S, Nicoletti G, Landuzzi L, Iezzi M, Campadelli-Fiume G, Lollini PL. (2013) Preclinical therapy of disseminated HER-2+ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. *PLoS Pathogens*; 9: e1003155.
21. Ianzano ML, Croci S, Nicoletti G, Palladini A, Landuzzi L, Grosso V, Ranieri D, Dall'Ora M, Santeramo I, Urbini M, De Giovanni C, Lollini P-L, Nanni P. (2014) Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice. *Oncotarget*; 5: 108-119.
22. De Giovanni C, Nicoletti G, Quagliano E, Landuzzi L, Palladini A, Ianzano ML, Dall'Ora M, Grosso V, Ranieri D, Laranga R, Croci S, Amici A, Penichet ML, Iezzi M, Cavallo F, Nanni P, Lollini P-L. (2014) Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2. *Breast Cancer Research*; 16:R10.
23. Castagnoli L, Iezzi M, Ghedini GC, Ciravolo V, Marzano G, Lamolinara A, Zappasodi R, Gasparini P, Campiglio M, Amici A, Chiodoni C, Palladini A, Lollini PL, Triulzi T, Menard S, Nanni P, Tagliabue E, Pupa SM. (2014) Activated d16HER2 homodimers and Src kinase mediate optimal efficacy for trastuzumab. *Cancer Research*; 74:6248-59.
24. Landuzzi L, Ianzano ML, Nicoletti G, Palladini A, Grosso V, Ranieri D, Dall'Ora M, Raschi E, Laranga R, Gambarotti M, Picci P, De Giovanni C, Nanni P, Lollini P-L.

- (2014) Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53 related sarcomas. *Oncotarget*; 15: 11924-38.
25. Croci S*, Nanni P*, Palladini A*, Nicoletti G, Grosso V, Benegiamo G, Landuzzi L, Lamolinara A, Ianzano ML, Ranieri D, Dall'Ora M, Iezzi M, De Giovanni C, Lollini P-L. (2015) IL-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis. *Breast Cancer Research*; 17:70. *contributed equally
 26. Leoni V, Gatta V, Palladini A, Nicoletti G, Ranieri D, Dall'Ora M, Grosso V, Rossi M, Alviano F, Bonsi L, Nanni P, Lollini P-L, Campadelli-Fiume G. (2015) Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases, *Oncotarget*; 6: 34774.
 27. Castagnoli L, Ghedini GC, Koschorke A, Triulzi T, Dugo M, Gasparini P, Casalini P, Palladini A, Iezzi M, Lamolinara A, Lollini P-L, Nanni P, Chiodoni C, Tagliabue E, Pupa SM. (2017) Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer, *Oncogene*; 36:1721.
 28. Palladini A, Nicoletti G, Lamolinara A, Dall'Ora M, Balboni T, Ianzano ML, Laranga R, Landuzzi L, Giusti V, Ceccarelli C, Santini D, Taffurelli M, Di Oto E, Asioli S, Amici A, Pupa SM, De Giovanni C, Tagliabue E, Iezzi M, Nanni P, Lollini P-L. (2017) HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response, *Oncotarget*; 8:54444-54458.
 29. Palladini A, Thrane S, Janitzek CM, Pihl J, Clemmensen SB, de Jongh WA, Clausen TM, Nicoletti G, Landuzzi L, Penichet ML, Balboni T, Ianzano ML, Giusti V, Theander TG, Nielsen MA, Salanti A, Lollini PL, Nanni P, Sander AF. (2018) Virus-like particle display of HER2 induces potent anti-cancer responses, *Oncoimmunology*; 7(3): e1408749.
 30. Palladini A, Landuzzi L, Lollini PL, Nanni P (2018). Cancer immunoprevention: from mice to early clinical trials. *BMC Immunol*. 19(1):16.
 31. Nanni P, De Giovanni C, Burocchi A, Nicoletti G, Landuzzi L, Palladini A, Ianzano ML, Arioli I, Colombo MP, Lollini P-L. (2018) OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis. *Oncoimmunology*; 7(8): e1465164.
 32. De Giovanni C, Nanni P, Landuzzi L, Ianzano ML, Nicoletti G, Croci S, Palladini A*, Lollini P-L*. (2019) Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis. *BMC Cancer*; 19(1):126. *contributed equally
 33. De Giovanni C*, Landuzzi L*, Palladini A*, Ianzano ML, Nicoletti G, Ruzzi F, Amici A, Croci S, Nanni P, Lollini P-L. (2019) Cancer Vaccines Co-Targeting HER2/Neu and IGF1R. *Cancers (Basel)*. 11(4): E517. *contributed equally
 34. Nanni P, Landuzzi L, Manara MC, Righi A, Nicoletti G, Cristalli C, Pasello M, Parra A, Carrabotta M, Ferracin M, Palladini A, Ianzano ML, Giusti V, Ruzzi F, Magnani M, Donati DM, Picci P, Lollini PL, Scotlandi K. (2019) Bone sarcoma patient-

derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations. *Sci Rep.* 9(1):12174.

35. De Giovanni C, Nicoletti G, Landuzzi L, Palladini A, Lollini PL, Nanni P. (2019) Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model. *Cancers.* 11(12): E1889.

36. Lamberti G, Sisi M, Andrini E, Palladini A, Giunchi F, Lollini PL, Ardizzoni A, Gelsomino F. (2020) The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players? *Cancers.* 12(11):3129.

37. Landuzzi L*, Palladini A*, Ceccarelli C, Asioli S, Nicoletti G, Giusti V, Ruzzi F, Ianzano ML, Scalambra L, Laranga R, Arigoni M, Olivero M, Calogero R, De Giovanni C, Dall'Ora M, Di Oto E, Santini D, Foschini MP, Cucchi MC, Zanotti S, Taffurelli M, Nanni P, Lollini P-L. (2020) Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft. *Sci Rep.* 11(1):1563.

38. Angelicola S, Ruzzi F, Landuzzi L, Scalambra L, Gelsomino F, Ardizzoni A, Nanni P, Lollini P-L, Palladini A. (2021) IFN- γ and CD38 as possible factors in hyperprogressive disease development. *Cancers.* 13(2):309.

39. De Giovanni C, Landuzzi L, Palladini A, Nicoletti G, Nanni P, Lollini P-L. (2021) HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy. *Cells.* 10(7):1808.

40. Giusti V, Ruzzi F, Landuzzi L, Ianzano ML, Laranga R, Nironi E, Scalambra L, Nicoletti G, De Giovanni C, Olivero M, Arigoni M, Calogero R, Nanni P, Palladini A*, Lollini PL*. (2021) Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression. *Oncogenesis.* 10(11):77. *contributed equally

41. Di Federico A, Filetti M, Palladini A, Giusti R, Piras M, De Giglio A, Ardizzoni A, Gelsomino F. (2022) EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR TKIs: two cases and review of the literature. *Translational Lung Cancer Research.* 11(3):497.

42. Ruzzi F, Angelicola S, Landuzzi L, Nironi E, Semprini MS, Scalambra L, Altimari A, Gruppioni E, Fiorentino M, Giunchi F, Ferracin M, Astolfi A, Indio V, Ardizzoni A, Gelsomino F, Nanni P, Lollini PL, Palladini A. (2022). ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC. *Translational Lung Cancer Research.* 11(11):2216. 4

43. Ruzzi F*, Palladini A*, Clemmensen S, Strøbæk A, Buijs N, Domeyer T, Dorosz J, Soroka V, Grzadziela D, Rasmussen CJ, Nielsen IB, Soegaard M, Semprini MS, Scalambra L, Angelicola S, Landuzzi L, Lollini PL, Thorn M. (2022) Prevention and Therapy of Metastatic HER-2+ Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine. *Biomedicines.* 10(10):2654. *contributed equally

44. Andrini E, Federico AD, Sisi M, Rosellini M, Palladini A, Lamberti G, Giglio A, Gelsomino F. (2022) Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies. *Immunotherapy* 14(16):1329-1340.

45. Di Federico A, De Giglio A, Gelsomino F, De Biase D, Giunchi F, Palladini A, Sperandi F, Melotti B, Ardizzoni A. (2022) Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes. *Cancers (Basel)*. 14(14):3472.
46. Cavazzoni A, Palladini A. (2023) Editorial: Inhibitors of CDK family: New perspective and rationale for drug combination in preclinical models of solid tumors. *Front Oncol*. 13:1180650.
47. Ruzzi F, Semprini MS, Scalambra L, Palladini A, Angelicola S, Cappello C, Pittino OM, Nanni P, Lollini PL. (2023) Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy. *Int J Mol Sci*. 24(16):12963.
48. Ruzzi F, Semprini MS, Scalambra L, Angelicola S, Cappello C, Pittino OM, Nanni P, Palladini A*, Lollini PL (2024)*. Functional evaluation of circulating anti-cancer antibodies with a 3D tumor cell growth inhibition assay. *Methods Cell Biol*. 190:75-86. *contributed equally
49. Ruzzi F, Cappello C, Semprini MS, Scalambra L, Angelicola S, Pittino OM, Landuzzi L, Palladini A, Nanni P, Lollini P (2024). Lipid rafts, caveolae, and epidermal growth factor receptor family: friends or foes? *Cell Commun Signal*. 22(1): 489.
50. Di Federico A, Angelicola S, Frascino M, Siracusa I, Bisanti B, Ruzzi F, Semprini MS, De Jonge H, De Giglio A, Sperandi F, Brocchi S, Melotti B, Giunchi F, Gruppioni E, Altimari A, Lollini PL, Ardizzoni A, Palladini A*, Gelsomino F* (2024). Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations. *JCO Precis Oncol*. 8: e2400240. *contributed equally; Palladini is also the corresponding author
51. Angelicola S, Giunchi F, Ruzzi F, Frascino M, Pitzalis M, Scalambra L, Semprini MS, Pittino OM, Cappello C, Siracusa I, Chillico IC, Di Noia M, Turato C, De Siervi S, Lescai F, Ciavattini T, Lopatriello G, Bertoli L, De Jonge H, Iamele L, Altimari A, Gruppioni E, Ardizzoni A, Rossato M, Gelsomino F, Lollini PL, Palladini A. (2025) PD-L1 and IFN- γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD). *J Transl Med*. 23(1):2.
52. Laura S, Ruzzi F, Pittino OM, Semprini MS, Cappello C, Angelicola S, Palladini A, Nanni P, Goksøyr L, Fougeroux C, Penichet ML, Sander AF and Lollini P-L. Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma. (2025)
53. Cappello C, Ruzzi F, Consoli J, Semprini MS, Scalambra L, Pittino OM, Angelicola S, Palladini A, Thorn M, Nanni P, Lollini PL. Development of cellular models expressing cynomolgus (*Macaca fascicularis*) HER2 for the functional evaluation of cross-reactive anti-human HER2 response. *Front Pharmacol*. 2025 Nov 13;16:1675875.
54. Cavazzoni A, Pagano Mariano M, Palladini A, Digiacomo G, La Monica S, Bonelli M, Galetti M, Pace I, Roncarati R, Giovannetti E, Aretini P, Minari R, Treccani M, Pluchino M, Lagrasta CA, Angelicola S, Mazzaschi G, Bordi P, Gelsomino F,

Agustoni F, Petronini PG, Tiseo M, Ferracin M, Alfieri R. Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC. *Lung Cancer*. 2026 Mar;213:108939.

55. Pittino OM Semprini MS, Lac2Lab, Ruzzi F, Angelicola A, Capello C, Scalambra L, Frascino M, Michel P, Nanni P, Lollini P-L, Palladini A. Alternatives for fetal bovine serum (FBS) and sustainability of milk derivatives in cell culture. *Biological Research* 2026 Mar 28;59(1):30.

56. Semprini MS, Pittino OM, Ippolito L, Rinaldi M, Prandi B, Tedeschi T, Fabiani T, Ruzzi F, Angelicola S, Cappello C, Scalambra L, Frascino M, Chillico IC, Lollini P-L, Palladini A. Requalified bovine milk as a sustainable supplement for cell cultures. *Discover Food* 2026, 6, 210.

57. Angelicola S, Frascino M, Chillico IC, Michel PLS, Pistone D, Semprini MS, Pittino OM, Ardizzoni A, Alessio NL, Agustoni F, Gelsomino F, Lollini P-L, Palladini A. Beyond Immune Surveillance: IFN- γ and PD-L1 as Shapers of Tumor Plasticity in Non-Small Cell Lung Cancer (NSCLC). *Frontiers in Immunology*. *In press*

Pavia, 02/10/26

Prof.ssa Arianna Palladini

Arianna Palladini